Indication
Adenocarcinoma of the Lung
25 clinical trials
37 products
13 drugs
Clinical trial
A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a Single Agent and In Combination With Pembrolizumab in Subjects With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2023-08-25
Product
PY159Product
PY159/PembrolizumabProduct
PY159 PembrolizumabProduct
PY314Clinical trial
A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY314 as a Single Agent and In Combination With Pembrolizumab in Subjects With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2023-08-31
Product
PY314 + PembrolizumabProduct
AZD5335Clinical trial
FONTANA: A Modular Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors.Status: Recruiting, Estimated PCD: 2027-11-01
Product
AZD5305Product
RAIN-32Clinical trial
A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors (MANTRA-2)Status: Terminated, Estimated PCD: 2023-10-15
Product
IBI188Clinical trial
Phase Ib Study to Evaluate the Efficacy, Safety and Tolerability of IBI188 Combination Therapy in Subjects With Advanced MalignanciesStatus: Terminated, Estimated PCD: 2022-07-30
Product
GM-CSFProduct
BevacizumabProduct
PemetrexedProduct
Cisplatin/CarboplatinProduct
SintilimabClinical trial
First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid TumoursStatus: Recruiting, Estimated PCD: 2024-01-01
Product
AMT-151Clinical trial
Positron-Emission Tomography Detection of Sodium-Glucose Transport for Early Diagnosis of Lung CancerStatus: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Phase I-II Trial of Combined PKCι and mTOR Inhibition for Patients With Advanced or Recurrent Lung Cancer (NSCLC and SCLC) Without Standard Treatment OptionsStatus: Completed, Estimated PCD: 2023-04-24
Product
AuranofinProduct
SirolimusClinical trial
Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR)Status: Recruiting, Estimated PCD: 2025-12-31
Product
IpilimumabProduct
NivolumabClinical trial
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to ErlotinibStatus: Completed, Estimated PCD: 2020-12-18
Product
TrametinibClinical trial
A Phase II Study of Circulating Tumor DNA Directed Consolidation Durvalumab (MEDI4736) Following Induction and Concurrent Durvalumab With SABR for Stage I NSCLC. SCION: SABR and Checkpoint Inhibition Of NSCLCStatus: Recruiting, Estimated PCD: 2026-12-01
Product
DurvalumabDrug
ErlotinibClinical trial
Perioperative Analysis of Binimetinib and Palbociclib in RAS-Driven TumorsStatus: Withdrawn, Estimated PCD: 2025-09-30
Product
BinimetinibProduct
PalbociclibClinical trial
Phase 1 Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid TumorsStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)Status: Recruiting, Estimated PCD: 2026-12-31
Product
SotorasibClinical trial
A Phase II Study of Osimertinib to Suppress the Progression of Remaining Ground-glass Opacity Nodule (GGN) for Actionable EGFR Mutation-positive Stage IB-IIIA Lung AdenocarcinomaStatus: Recruiting, Estimated PCD: 2025-12-01
Product
OsimertinibDrug
cyclophosphamideDrug
fludarabineClinical trial
Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLCStatus: Active (not recruiting), Estimated PCD: 2019-04-16
Drug
AN0025Clinical trial
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified CutoffStatus: Recruiting, Estimated PCD: 2025-09-30
Drug
SpartalizumabClinical trial
Efficacy and Safety of Tislelizumab Combined With Platinum-containing Drug Chemotherapy in First-line Treatment of Lung Adenocarcinoma With Asymptomatic Brain MetastaticStatus: Recruiting, Estimated PCD: 2025-04-12
Product
Tislelizumab,PlatinumDrug
MetforminDrug
TiragolumabProduct
TislelizumabClinical trial
Neoadjuvant Tislelizumab and Platinum-Based Doublet Chemotherapy in Stage II-IIIB EGFR-Mutated Lung Adenocarcinoma With PD-L1 Positive Expression -- A Phase II Study (DuoVitality)"Status: Recruiting, Estimated PCD: 2025-06-30
Drug
pemetrexedProduct
cis-platemumProduct
CarboplatinClinical trial
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)Status: Active (not recruiting), Estimated PCD: 2019-05-26
Product
VeliparibClinical trial
Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung AdenocarcinomaStatus: Completed, Estimated PCD: 2018-01-01
Drug
CisplatinClinical trial
A Single-armed Phase Ⅱ Study of Bevacizumab Maintenance Therapy After Chemoradiotherapy for Locally Advanced Lung AdenocarcinomaStatus: Completed, Estimated PCD: 2021-12-10
Drug
AtezolizumabProduct
Concurrent ChemotherapyClinical trial
Phase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing CancersStatus: Active (not recruiting), Estimated PCD: 2025-03-01
Product
huCART-mesoClinical trial
A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-mutated, Non-Small Cell Lung Cancer (NSCLC) After Treatment With Osimertinib (AZD9291, Tagrisso)Status: Completed, Estimated PCD: 2022-05-25
Product
osimertinibClinical trial
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2027-12-31
Drug
LurbinectedinDrug
T-VEC